MabCure, Inc. Announces Completion of Its Ovarian Cancer Diagnostic Study in Thailand

Data Analysis Expected to be Completed in Six Months

NEW YORK--(BUSINESS WIRE)-- MabCure, Inc. (OTCBB:MBCI), a leading developer of antibody based diagnostics and treatments for ovarian, prostate and other cancers today announced that it has recently completed its prospective diagnostic clinical study of 150 patients presenting with pelvic mass. The study provides invaluable blood and urine specimen which will be analyzed by MabCure diagnostic antibodies for the detection of Ovarian Cancer. The test was conducted in the Ramathibodi Hospital and the Thai National Cancer Institute, Bangkok, Thailand.

The lack of a reliable diagnostic tool to detect ovarian cancer in its early stage is the major cause of poor prognosis of ovarian cancer patients (5 year survival of less than 25% for stage 3 and 4 disease). Women presenting with pelvic mass in the U.S. have a 1 in 4 chance to be diagnosed with ovarian cancer. Clinical studies have shown that women diagnosed with ovarian cancer have better prognosis if they are operated on by gynecological oncologists compared to general surgeons. Therefore, it is important to distinguish between ovarian cancer patients and those having benign tumors of the ovaries prior to surgery. MabCure pilot study, presented at the annual meeting of Society of Gynecological Oncologists (SGO) in Florida (March 2011) demonstrated that its diagnostic antibodies were able to distinguish between benign and ovarian cancer by a simple blood test. The completed prospective Thai study provides MabCure with unique opportunity to examine the blood and urine specimen obtained from the enrolled patients and further evaluate the performance of its diagnostic antibodies on a much larger scale.

CEO of MabCure, Amnon Gonenne stated, “This is a very exciting time for MabCure and its shareholders. We are looking forward to completing this test with our antibodies for the diagnosis of ovarian cancer within the next six months. This will hopefully contribute to our progress in developing a reliable test that will detect this disease early enough to give women a fighting chance.”

About MabCure

MabCure is a U.S. biotechnology company whose mission is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which the company plans to develop as diagnostic tools, imaging agents and therapeutic drugs to treat lethal cancers. The company’s initial focus is on the development of novel diagnostic tests for the early detection of ovarian, prostate, and colorectal cancers, each with multi-billion dollar global market potential. MabCure is also currently exploring the potential of its anti-melanoma antibodies for the development of imaging and therapeutic agents. The company is headquartered in Hasselt, Belgium. For more information about MabCure and to sign up for e-mail updates, visit www.mabcure.com.

This news release contains “forward-looking statements.” Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.



CONTACT:

Carpe DM, Inc.
Stuart Fine, 908-469-1788

KEYWORDS:   United States  Asia Pacific  North America  New York  Thailand

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Consumer  General Health

MEDIA:

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.